3 completed, 1 unknown. 2 Phase 2, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow CRV-431: new trials by email Literature Review of CRV-431 trials Research Report on CRV-431
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects [14C]-rencofilstat 225mg - NASH With Fibrosis | Early Phase 1 | Completed | Hepion Pharmaceuticals, Inc. | 6 | 2023-03-01 | 2024-10-03 |
| A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis Rencofilstat, Placebo - Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver | Phase 2 | Unknown | Hepion Pharmaceuticals, Inc. | 120 | 2022-10-15 | 2024-05-03 |
| A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects CRV431 75mg, Placebo (1 softgel), CRV431 225mg - NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver | Phase 2 | Completed | Hepion Pharmaceuticals, Inc. | 47 | 2020-06-23 | 2022-07-15 |
| A Study in Healthy Volunteers CRV431, Placebo, TDF - Hepatitis B, Infectious Disease | Phase 1 | Completed | Hepion Pharmaceuticals, Inc. | 92 | 2019-07-09 | 2021-12-01 |
Non-alcoholic Fatty Liver Disease (3) · Liver Cirrhosis (2) · Communicable Diseases (1) · Hepatitis B (1) · Liver Diseases (1)
Hepion Pharmaceuticals, Inc. (4)
United States (3) · France (1) · Mexico (1) · Puerto Rico (1) · United Kingdom (1)
Carlos Canizares, R.Ph. (1) · Jill Greytok (1) · Litza McKenzie, MD (1) · Stephen Harrison, MD (1)